Carl-Wilhelm E. Vogel, MD, PhD

Carl-Wilhelm E. Vogel, MD, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 721-4309

Full Member (Non-Aligned), University of Hawaiʻi Cancer Center

Academic Appointment(s):
Researcher (Professor), University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa
Clinical Professor, Department of Pathology, John A. Burns School of Medicine, University of Hawaiʻi at Mānoa
Graduate Faculty, Cell and Molecular Biology Program, John A. Burns School of Medicine, University of Hawaiʻi at Mānoa
Adjunct Professor, Institute for Micronesian Health and Aging Studies, University of Guam

Degree(s):
MS, PhD, Biochemistry, University of Hamburg
MD, University of Hamburg
Diplomate in Clinical Pathology, American Board of Pathology
Life Fellow, College of American Pathologists
Overseas Fellow, Royal Society of Medicine, London

Research Focus

For over three decades Dr. Vogel has studied the human complement system with a particular emphasis on its potential role in cancer. He has used cobra venom factor (CVF), a structural and functional analog of the activated form of complement component C3, as a molecular tool to study the structure/function of human C3. Over the last several years he and his colleagues have succeeded in generating a derivative of human C3 with CVF-like functions, including the temporary depletion of complement activity in serum, both in vitro and in vivo. The human C3 derivative, termed "humanized CVF" (hCVF), represents a novel experimental therapeutic reagent for complement depletion, with possible clinical applications in many diseases where complement is involved in the pathogenesis of the disease process. Multiple pre-clinical studies have shown the efficacy of hCVF, with no adverse effects. hCVF has been shown to have a dramatic survival benefit in a mouse model of lymphoma treated with a monoclonal anti-lymphoma antibody. hCVF has also been shown to be effective in multiple non-cancer diseases, including age-related macular degeneration (AMD), myasthenia gravis, myocardial infarction reperfusion injury, arthritis, paroxysmal nocturnal hemoglobinuria (PNH), and others. Treatment with hCVF also reduces the generation of anti-Factor VIII antibodies in hemophilia. Dr. Vogel's laboratory continues to investigate the efficacy of complement depletion with hCVF in multiple additional models of disease. He and his colleagues are also trying to develop novel forms of hCVF exhibiting different pharmacokinetic properties.

Dr. Vogel is Principal Investigator of consecutive U56 and U54 Grants since 2003 as part of NCI's Minority Institution/Cancer Center Partnership program (MI/CCP), renamed Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) between the University of Hawaiʻi Cancer Center (UH Cancer Center) and the University of Guam (UOG). The current $5.5 million U54 grant is awarded through 2020. The partnership with UOG is a long-term partnership addressing cancer health disparities in Pacific Islanders in Hawaiʻi, Guam, and the U.S.-associated Pacific territories. It provides funding for joint research projects, training programs, and regionally important outreach.

Selected Publications

Hew BE, Fritzinger DE, Pangburn MK, Vogel C-W. (2019). Identification of Functionally Important Amino Acid Sequences in Cobra Venom Factor Using Human C3/Cobra Venom Factor Hybrid Proteins, Toxicon 167 (2019), 106-116. PMID 31207349

Robinett HR, Leon Guerrero RT, Peterson JA, Ward DC, Palafox NA, Vogel C-W. (2019). A Unique Partnership between the University of Hawaii Cancer Center and the University of Guam: Fifteen Years of Addressing Cancer Health Disparities in Pacific Islanders in Guam and Hawaii. Hawaii J. Med. Pub. Health 78 (2019), 205-207. PMID pending.

Ing M, Hew BE, Fritzinger DC, Delignat S, Lacroix-Desmazes S, Vogel C-W, Rayes J. Absence of a Neutralizing Antibody Response to Humanized Cobra Venom Factor in Mice. Mol Immunol, 97 (2018), 1-7. PMID 29525557.

Vogel C-W, Fritzinger DC. Cobra Venom Factor: The Unique Component of Cobra Venom that Activates the Complement System. In: Handbook of Toxinology. Snake Venoms. (P. Gopalakrishnakone, H. Inagaki, A.K. Mukherjee, C.-W. Vogel, Eds.), pp. 345-404. Springer Science+Business Media, Dordrecht, The Netherlands (2017).

Vogel C-W, Finnegan PW, Fritzinger DC. (2014). Humanized Cobra Venom Factor: Structure, Activity, and Therapeutic Efficacy in Preclinical Disease Models. Mol Immunol 61, 191-203. PMID: 25062833.

Publication list via PubMed

Selected Patents

Vogel, C.-W., Finnegan, P.W., Rayes, J., Lacroix-Desmazes, S. Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity. Japanese Patent No. 6488376 (2019)

Vogel, C.-W., Fritzinger, D.C. Human Complement C3 Derivatives with Cobra Venom Factor-Like Function. U.S. Patent No. 8,632,780 (2014)

Active Grants

C.-W. Vogel, Principal Investigator; D. Ward and N. Palafox, MPIs
NCI
2U54 CA143727-A1, Comprehensive Partnership to Advance Cancer Health Equity
"University of Guam/University of Hawaiʻi Cancer Center Partnership"
September 2015 – August 2020, $5,480,992 (plus supplements)

C.-W. Vogel, Co-Investigator; D. Reutens, PI
DOD, Awarded through University of Queensland
W81XWH-17-1-0670.
“Targeting Complement in Post-traumatic Epiletogenesis”
September 2017 - September 2020, $545,005.

C.-W. Vogel, Consultant; J.W. Larrick, B. Yu, MPIs
NIH/NIDDK, Awarded through Panorama Research
1 R43DK116376-01
“Novel Therapy for Goodpasture Syndrome”
January 2018 – December 2019, $210,185